Both medications are excellent. The right choice depends on your goals, budget, and tolerance. Here is the honest comparison — efficacy data, dosing, side effects, and cost — written by a physician who prescribes both daily.
Tirzepatide produces greater average weight loss but costs more and has a newer safety track record. Semaglutide is more established, costs roughly half as much, and still produces clinically significant weight loss for most patients. Both are first-line options. There is no wrong answer.
Until 2025, the question "which is more effective" was answered by indirect comparison across different clinical trials. That changed with SURMOUNT-5, the first large randomized head-to-head trial directly comparing tirzepatide (up to 15 mg) with semaglutide (up to 2.4 mg) in adults with obesity.
Results at 72 weeks:
Tirzepatide produced roughly 6.5 percentage points more weight loss on average — a clinically meaningful difference, but not a landslide. A substantial minority of semaglutide patients achieved weight loss in tirzepatide's range, and vice versa. Individual response matters more than the average gap.
| Factor | Semaglutide | Tirzepatide |
|---|---|---|
| Mechanism | GLP-1 receptor agonist (single pathway) | Dual GIP + GLP-1 receptor agonist |
| Brand names | Wegovy and the Wegovy pill (weight management); Ozempic and Rybelsus (type 2 diabetes only) | Zepbound (weight management); Mounjaro (type 2 diabetes only) |
| Manufacturer | Novo Nordisk | Eli Lilly |
| Avg weight loss (trials) | 14.9% (STEP 1), 13.7% (SURMOUNT-5) | 22.5% (SURMOUNT-1), 20.2% (SURMOUNT-5) |
| Dose range | 0.25 – 2.4 mg/week (Wegovy pen; a Wegovy HD 7.2 mg dose also exists) | 2.5 – 15 mg/week (2.5 mg steps: 5, 7.5, 10, 12.5, 15) |
| Titration length | ~16 weeks to max dose | ~16 weeks to max dose |
| Delivery | Weekly subcutaneous injection | Weekly subcutaneous injection |
| Half-life | ~7 days | ~5 days |
| Side effects | GI (nausea, constipation, diarrhea) | GI (nausea, constipation, diarrhea) — similar |
| Cardiovascular outcome data | SELECT trial: 20% MACE reduction | SURPASS-CVOT ongoing |
| Medication cost | Manufacturer-direct (NovoCare) | Manufacturer-direct (LillyDirect) |
| Brand-name cash price | ~$1,300/month (Wegovy) | ~$1,059/month (Zepbound) |
Both drugs cause the same family of GI side effects (nausea, constipation, diarrhea, reflux, fatigue, occasional vomiting). Both peak in the first 2–4 weeks after each dose increase. In SURMOUNT-5, discontinuation rates due to side effects were similar between the two arms. Individual tolerance varies — some patients sail through one drug but struggle with the other for reasons we cannot always predict. Starting low and going slow, with appropriate anti-nausea support if needed, solves most side effect issues regardless of which drug you choose.
Many YourMD patients follow this trajectory: start on semaglutide, lose 10–15% of body weight, plateau or decide they want more, and switch to tirzepatide for the final push. This pattern takes advantage of semaglutide's lower cost during the initial loss phase and tirzepatide's greater potency when progress stalls. Your physician can support either strategy.
Pick semaglutide if cost, safety track record, or modest weight loss goals are your priorities. Pick tirzepatide if maximum weight loss, diabetes treatment, or dual-mechanism pharmacology matters most to you. Both will be managed by a board-certified physician at YourMD, both are brand medications billed and dispensed by NovoCare®, LillyDirect™, or your insurance-covered pharmacy (never compounded), both include a free async physician consult and unlimited messaging, and both can be switched if your first choice does not fit.
Both share the same class warnings: thyroid C-cell tumors in rodents (causal link in humans unconfirmed), pancreatitis, gallbladder disease. Contraindications are identical: personal or family history of medullary thyroid carcinoma, MEN 2, pregnancy, severe GI disease. Semaglutide has longer real-world safety data; tirzepatide's safety profile in trials is comparable.
No. Never combine GLP-1 agonists. If switching, stop one drug and start the other at the starter dose.
YourMD does not prescribe compounded GLP-1s. Your GLP-1 membership (GLP-1 Essential $79/month or GLP-1 Concierge $149/month) covers physician care, and the brand medication is billed separately by NovoCare®, LillyDirect™, or your insurance. If you have commercial coverage for Wegovy® or Zepbound®, your physician can write for the brand and the Concierge plan adds prior-authorization support. We can provide superbill documentation for HSA/FSA reimbursement of membership fees.
Start with the eligibility screening. Your YourMD physician will discuss both options, your medical history, and your goals in your free async consult — no appointment needed; if a phone or video visit is needed, your physician will contact you. Many patients start out leaning one way and find clarity once their physician has reviewed their specific situation.
Manufacturer-direct pricing + physician care
Best for first-time GLP-1 users and budget-conscious patients.
Start with SemaglutideManufacturer-direct pricing + physician care
Best for maximum weight loss, type 2 diabetes, or semaglutide plateau.
Start with TirzepatideNot sure? Start the free screening and your physician will help you choose.
Medical disclaimer: This page is educational and is not medical advice. Both medications are available only by prescription after a physician evaluation. Individual results vary. Side effects and contraindications are described on the individual medication pages. Page medically reviewed by Teja V. Surapaneni, MD, MS — Board-Certified Internal Medicine, licensed in Nevada, Washington, Oregon, and Wisconsin.
Last reviewed: April 17, 2026